Acerus Pharmaceuticals Corporation
14
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
21.4%
3 terminated/withdrawn out of 14 trials
76.9%
-9.6% vs industry average
50%
7 trials in Phase 3/4
90%
9 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men
Role: collaborator
A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections
Role: collaborator
Natesto Testosterone Nasal Gel for Hypogonadal Men
Role: collaborator
A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel
Role: lead
Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters
Role: collaborator
PK Study of Testosterone Nasal Gel (TBS-2) in Healthy Premenopausal Women
Role: lead
Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™
Role: lead
Efficacy and Tolerability of an Intra-Nasal Testosterone Product
Role: lead
Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder
Role: lead
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
Role: lead
Efficacy of an Intranasal Testosterone Product
Role: lead
NASOBOL in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers
Role: lead
Influence of Administration Route of Testosterone on Male Fertility
Role: lead
Dose Finding Study of Albuterol Sulfate in Patients With Intermittent or Persistent Mild Asthma
Role: lead
All 14 trials loaded